BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bielen R, Stumo SR, Halford R, Werling K, Reic T, Stöver H, Robaeys G, Lazarus JV. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. Harm Reduct J 2018;15:25. [PMID: 29751763 DOI: 10.1186/s12954-018-0230-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Perrett SE, Plimmer A, Shankar AG, Craine N. Prevalence of HCV in prisons in Wales, UK and the impact of moving to opt-out HCV testing. J Public Health (Oxf) 2020;42:423-8. [PMID: 32090269 DOI: 10.1093/pubmed/fdaa022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Dmitrieva A, Stepanov V, Svyrydova K, Lukash IG, Doltu S, Golichenko M, Kalivoshko V, Khanyukov E, Kosmukhamedova Z, Torkunov O, Zagrebelnyi O. More evidence or stronger political will: exploring the feasibility of needle and syringe programs in Ukrainian prisons. Harm Reduct J 2021;18:10. [PMID: 33468162 DOI: 10.1186/s12954-020-00459-z] [Reference Citation Analysis]
3 Moazen B, Dolan K, Saeedi Moghaddam S, Lotfizadeh M, Duke K, Neuhann F, Stöver H, Jahn A. Availability, Accessibility, and Coverage of Needle and Syringe Programs in Prisons in the European Union. Epidemiologic Reviews 2020;42:19-26. [DOI: 10.1093/epirev/mxaa003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Corcorran MA, Ludwig-Baron N, Cheng DM, Lioznov D, Gnatienko N, Patts G, So-Armah K, Blokhina E, Bendiks S, Krupitsky E, Samet JH, Tsui JI. The Hepatitis C Continuum of Care Among HIV-Positive Persons with Heavy Alcohol Use in St. Petersburg, Russia. AIDS Behav 2021;25:2533-41. [PMID: 33730255 DOI: 10.1007/s10461-021-03214-y] [Reference Citation Analysis]
5 Gaspar R, Liberal R, Tavares J, Morgado R, Macedo G. HIPPOCRATES® project: A proof of concept of a collaborative program for hepatitis C virus micro-elimination in a prison setting. World J Hepatol 2020; 12(12): 1314-1325 [PMID: 33442457 DOI: 10.4254/wjh.v12.i12.1314] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Palayew A, Stumo SR, Cooke GS, Hutchinson SJ, Jauffret-Roustide M, Maticic M, Harris M, Metwally AM, Razavi H, Lazarus JV; Hep-CORE Study Group. The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. PLoS One 2020;15:e0235715. [PMID: 32722701 DOI: 10.1371/journal.pone.0235715] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
7 Hariri S, Sharafkhah M, Alavi M, Roshandel G, Fazel A, Amiriani T, Motamed-Gorji N, Bazazan A, Merat S, Poustchi H, Malekzadeh R. A simple risk-based strategy for hepatitis C virus screening among incarcerated people in a low- to middle-income setting. Harm Reduct J 2020;17:56. [PMID: 32795371 DOI: 10.1186/s12954-020-00400-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sander G, Shirley-Beavan S, Stone K. The Global State of Harm Reduction in Prisons. J Correct Health Care 2019;25:105-20. [PMID: 31084277 DOI: 10.1177/1078345819837909] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
9 Behzadifar M, Azari S, Gorji HA, Martini M, Bragazzi NL. The hepatitis C virus in Iran: health policy, historical, ethical issues and future challenges. J Prev Med Hyg 2020;61:E109-18. [PMID: 32490276 DOI: 10.15167/2421-4248/jpmh2020.61.1.1438] [Reference Citation Analysis]
10 Jack K, Thomson BJ, Irving WL. Testing for hepatitis C virus infection in UK prisons: What actually happens? J Viral Hepat 2019;26:644-54. [DOI: 10.1111/jvh.13071] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
11 Gahrton C, Westman G, Lindahl K, Öhrn F, Dalgard O, Lidman C, Nilsson LH, Said K, Duberg AS, Aleman S. Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County. BMC Infect Dis 2019;19:955. [PMID: 31706284 DOI: 10.1186/s12879-019-4581-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Busschots D, Kremer C, Bielen R, Koc ÖM, Heyens L, Dercon E, Verrando R, Windelinckx T, Maertens G, Bourgeois S, Hens N, Matheï C, Robaeys G. Identification and treatment of viral hepatitis C in persons who use drugs: a prospective, multicenter outreach study in Flanders, Belgium. Harm Reduct J 2021;18:54. [PMID: 34001145 DOI: 10.1186/s12954-021-00502-7] [Reference Citation Analysis]
13 Gamkrelidze I, Pawlotsky JM, Lazarus JV, Feld JJ, Zeuzem S, Bao Y, Gabriela Pires Dos Santos A, Sanchez Gonzalez Y, Razavi H. Progress towards hepatitis C virus elimination in high-income countries: An updated analysis. Liver Int. 2021;41:456-463. [PMID: 33389788 DOI: 10.1111/liv.14779] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
14 Nakitanda AO, Montanari L, Tavoschi L, Mozalevskis A, Duffell E. Hepatitis C virus infection in EU/EEA and United Kingdom prisons: opportunities and challenges for action. BMC Public Health 2020;20:1670. [PMID: 33167912 DOI: 10.1186/s12889-020-09515-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Crespo J, Llerena S, Cobo C, Cabezas J, Cuadrado A. HCV Management in the Incarcerated Population: How Do We Deliver on This Important Front? Curr Hepatology Rep 2019;18:259-67. [DOI: 10.1007/s11901-019-00472-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
16 Jack K, Linsley P, Thomson BJ, Irving WL. How do people in prison feel about opt‐out hepatitis C virus testing? J Viral Hepat 2020;27:1003-11. [DOI: 10.1111/jvh.13338] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Bretaña NA, Gray RR, Cunningham EB, Betz-Stablein B, Ribeiro R, Graw F, Luciani F, Lloyd AR. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study. Addiction 2020;115:901-13. [PMID: 31633853 DOI: 10.1111/add.14830] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
18 Biondi MJ, Feld JJ. Hepatitis C models of care: approaches to elimination. CanLivJ 2020;3:165-76. [DOI: 10.3138/canlivj.2019-0002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Opitz-Welke A, Lehmann M, Seidel P, Konrad N. Medicine in the Penal System. Dtsch Arztebl Int 2018;115:808-14. [PMID: 30642429 DOI: 10.3238/arztebl.2018.0808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
20 Salari N, Darvishi N, Hemmati M, Shohaimi S, Ghyasi Y, Hossaini F, Bazrafshan MR, Akbari H, Mohammadi M. Global prevalence of hepatitis C in prisoners: a comprehensive systematic review and meta-analysis. Arch Virol 2022. [PMID: 35165781 DOI: 10.1007/s00705-022-05382-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Redman JS, Sterling RK. Treating HCV in a Captive Audience: Eradication Efforts in the Prison Microenvironment. American Journal of Gastroenterology 2018;113:1585-7. [DOI: 10.1038/s41395-018-0201-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
22 Jamin D, Vanderplasschen W, Sys O, Jauffret-Roustide M, Michel L, Trouiller P, Neisa A, Homen M, Mendes V, Stöver H. "My first 48 hours out": drug users' perspectives on challenges and strategies upon release from prison. Harm Reduct J 2021;18:32. [PMID: 33712032 DOI: 10.1186/s12954-021-00480-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Stöver H, Meroueh F, Marco A, Keppler K, Saiz de la Hoya P, Littlewood R, Wright N, Nava F, Alam F, Walcher S, Somaini L. Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe. BMC Public Health 2019;19:30. [PMID: 30621658 DOI: 10.1186/s12889-018-6357-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
24 Marco A, Domínguez-Hernández R, Casado MA. Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain. Rev Esp Sanid Penit 2020;22:66-74. [PMID: 32697276 DOI: 10.18176/resp.00012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Mehdiyev R, Alikhanova N, Gurbanova E. HIV/tuberculosis/hepatitis C virus services for incarcerated populations in Azerbaijan and the Eastern Europe Central Asia region. Curr Opin HIV AIDS 2019;14:66-70. [PMID: 30489347 DOI: 10.1097/COH.0000000000000513] [Reference Citation Analysis]
26 Enkelmann J, Gassowski M, Nielsen S, Wenz B, Roß S, Marcus U, Bremer V, Zimmermann R; DRUCK Study group. High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014: missed opportunities for hepatitis C testing. Harm Reduct J 2020;17:7. [PMID: 31924208 DOI: 10.1186/s12954-019-0338-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
27 Papaluca T, McDonald L, Craigie A, Gibson A, Desmond P, Wong D, Winter R, Scott N, Howell J, Doyle J, Pedrana A, Lloyd A, Stoove M, Hellard M, Iser D, Thompson A. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care. J Hepatol. 2019;70:839-846. [PMID: 30654067 DOI: 10.1016/j.jhep.2019.01.012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
28 Crowley D, Murtagh R, Cullen W, Keevans M, Laird E, McHugh T, McKiernan S, Miggin SJ, O'Connor E, O'Reilly D, Betts-Symonds G, Tobin C, Van Hout MC, Lambert JS. Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners. Harm Reduct J. 2019;16:42. [PMID: 31277665 DOI: 10.1186/s12954-019-0313-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
29 Biondi MJ, Feld JJ. Hepatitis C models of care: approaches to elimination. CanLivJ 2020;3:165-76. [DOI: 10.3138/canlivj-2019-0002] [Reference Citation Analysis]
30 Defante Ferreto LE, Guedes S, Braz Pauli F, Soligo Rovani S, Aní Caovilla Follador F, Paula Vieira A, Himovski Torres R, Colares Coelho H, Welter Wendt G. Seroprevalence and associated factors of HIV and Hepatitis C in Brazilian high-security prisons: A state-wide epidemiological study. PLoS One 2021;16:e0255173. [PMID: 34310633 DOI: 10.1371/journal.pone.0255173] [Reference Citation Analysis]
31 Stöver H, Tarján A, Horváth G, Montanari L. The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases. Harm Reduct J 2021;18:67. [PMID: 34187471 DOI: 10.1186/s12954-021-00506-3] [Reference Citation Analysis]
32 Crowley D, Avramovic G, Cullen W, Farrell C, Halpin A, Keevans M, Laird E, McHugh T, McKiernan S, Miggin SJ, Murtagh R, Connor EO, O'Meara M, Reilly DO, Lambert JS. New hepatitis C virus infection, re-infection and associated risk behaviour in male Irish prisoners: a cohort study, 2019. Arch Public Health 2021;79:97. [PMID: 34103080 DOI: 10.1186/s13690-021-00623-2] [Reference Citation Analysis]
33 Alam F, Wright N, Roberts P, Dhadley S, Townley J, Webster R. Optimising opioid substitution therapy in the prison environment. Int J Prison Health 2019;15:293-307. [PMID: 31532339 DOI: 10.1108/IJPH-12-2017-0061] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Gallacher J, McPherson S. Progress towards micro-elimination of hepatitis C in the custodial setting. J Viral Hepat 2021;28:300-1. [PMID: 33131191 DOI: 10.1111/jvh.13428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Armstrong-Mensah E, Dada D, Rupasinghe R, Whately H. Injecting substance use in prisons in the United States: a case for needle exchange programs. Am J Drug Alcohol Abuse 2021;47:273-9. [PMID: 33596124 DOI: 10.1080/00952990.2021.1872587] [Reference Citation Analysis]